This Tuesday morning session will discuss clinical and field applications of mass spectrometry, such as proteomic genotyping, detection of cancer tumors and metastases, tissue profiling, and therapeutic drug monitoring. It will be chaired by Alan Rockwood of Rockwood Scientific Consulting and will be held in Ballroom 6CF from 8:30 to 10:30 a.m.
This Tuesday morning session will discuss clinical and field applications of mass spectrometry, such as proteomic genotyping, detection of cancer tumors and metastases, tissue profiling, and therapeutic drug monitoring. It will be chaired by Alan Rockwood of Rockwood Scientific Consulting and will be held in Ballroom 6CF from 8:30 to 10:30 a.m.
This session’s first presentation will be given by Christopher Shuford of Laboratory Corporation of America and is titled “Proteomic Genotyping, Now at Your Fingertips.” His talk will discuss the development of a generic bottom-up proteomic assay for identifying the Apo1 genotype of a patient. The assay provides the ability to genotype using a proteomic workflow with noninvasive in-home blood collection devices.
The next talk will be presented by Cornelia Koy of Proteome Center Rostock, in Rostock, Germany. Her presentation, titled “Mass Spectrometry Guides Western Blot Screening for Presence of Metastases in Lymph Nodes from Breast Cancer Patients,” will describe how MS-guided Western blotting allows metastasis detection in lymph nodes due to tissue-dependent expression of ezrin truncations.
Rémi Longuespée of the University of Heidelberg, Heidelberg, Germany will then give a talk titled “Rapid Detection of 2-Hydroxyglutarate in Tumor Frozen Sections by MALDI-TOF Mass Spectrometry.” This presentation will describe the first MALDI-TOF-based test for the intraoperative diagnosis of isocitrate dehydrogenase mutation status, which is important in the classification of brain tumors.
The next presentation, titled “Comparison of High- and Low-Resolution MS Data for Direct Tissue Profiling on a Way from Laboratory to Clinic,” will be given by Igor Popov of the Moscow Institute of Physics and Technology. His talk will discuss how low-resolution spectra preserve distinctive features of brain tumor samples and can possibly be used in sample classification.
Xiaolei Xie of Thermo Fisher Scientific in San Jose, California, will then present “Integrating Inborn Errors of Metabolism and Hemoglobin Variant Clinical Research into a Single HRAM Mass Spectrometer Workflow.” This presentation will describe the development of a high-resolution, high-throughput workflow for quantifying amino acids and acylcarnitines, and identifying hemoglobin variants in dried blood spot samples.
This session’s final presentation, titled “Free Fraction Analysis for Therapeutic Drug Monitoring of Antiepileptic Drugs,” will be given by Emily Barrey of MilliporeSigma, Bellefonte, Pennsylvania. Her presentation will discuss a simple, easily automated solid-phase microextraction method for quantitating the free fraction of the drugs pregabalin, levetiracetam, lamotrigine, felbamate, carbamazepine, and clonazepam.
Measuring Stress and Reproductive Hormones in Dolphins with UPLC
November 25th 2024A recent study measured stress and reproductive hormones in three stocks of free-ranging bottlenose dolphins inhabiting different natural salinities across the Gulf of Mexico, with hormones extracted from the blubber of 82 remotely biopsied dolphins and quantified using ultra performance liquid chromatography (UPLC) coupled with orbitrap fusion mass spectrometry.
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.